Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sActRIIB
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
sActRIIB is a recombinant protein, often engineered as an Fc-fusion protein, that functions as a ligand trap for the Activin Receptor Type IIB (ActRIIB). It binds to and sequesters multiple ligands, including myostatin (MSTN), activin A, and growth/differentiation factor 11 (GDF11), thereby inhibiting their signaling through ActRIIB. This inhibition promotes skeletal muscle growth (hypertrophy) and can lead to a reduction in fat mass.
- Other names
- soluble activin type IIB receptorsoluble ActRIIB
02
Targets
Activin AINHBB (Activin B)BMP9 (Bone morphogenetic protein 9)GDF11 (Growth differentiation factor 11)GDF8 (Myostatin)
Beyond the preview
Go deeper on sActRIIB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sActRIIB.